Agilent Technologies (A) Stock Forecast & Price Target

Agilent Technologies is viewed positively because its Q3 organic sales growth of 7.3% beat estimates, led by about 10% growth in Life Sciences and Diagnostics and strong pharma, where revenue rose 9% organically excluding CDMO. The outlook is further supported by synchronized product-cycle momentum across LC, GC, and ICP-MS platforms, book-to-bill above 1x, and early reshoring-related orders that broaden the long-term opportunity in drug manufacturing. Its exposure to sticky biopharma, chemical, and advanced materials end markets, plus only about 8% academic/government drag and improving margins, supports confidence that growth and earnings can stay above peers.

Agilent Technologies is viewed negatively because consensus already assumes durable organic growth and meaningful margin expansion, leaving little room for disappointment if execution on IGNITE falls short. Its earnings mix is exposed to cyclical end markets, with about 25% of sales tied to chemical and advanced materials and another 10% to environmental/forensics, while 18% of sales come from China, a concentration well above the peer average of about 12%. Management also faces risk from tariffs, sales phasing, weather, and a mixed acquisition record, so any macro deterioration, share loss, or weaker-than-expected operating leverage could pressure the stock.